BsAbs for Signaling Interference

As an unparalleled antibody development and manufacturer, Creative Biolabs is proud to offer high affinity bispecific antibodies (BsAbs) for both academic and industrial purposes. Based on our well established BsAb production platform, we offer a variety of BsAbs for signaling interference, including BsAbs for receptor signaling interference, BsAbs blocking two proangiogenics, and BsAbs blocking two proinflammatory cytokines.

Signaling pathway is a set of molecules in a cell which work together to control one or more cell functions, for example, cell division or cell death. When the first molecule in a pathway receives a signal, it activates another molecule. This process is repeated until the last molecule is activated and the cell function is carried out. However, abnormal activation of signaling pathways may result in cancer, thus developing potent drugs to block these pathways has attracted a lot of attention. With the highly progress of novel BsAb technology, BsAb is able to block signaling pathway to block cancer cell growth and kill cancer cells. Creative Biolabs is proud to offer a number of novel BsAbs for signaling interference.

BsAbs for Receptor Signaling Interference

Tumor cells/tissues often have abnormal angiogenic development, cell proliferation and cell motility, thus ligand-receptor interactions in these pathways are great targets for cancer treatment. (scFv)2-HSA BsAb, dual-action Fab (DAF)-IgG or 2 in 1-IgG, have been engineered to bind receptor tyrosine kinases (RTKs ) such as Her family or insulin-like growth factor (IGF) receptors, metastasis factors such as c-MET, angiogenesis or vasculogenesis factors such as angiopoietin 2 (Ang2), and tumor necrosis factor(TNF). Creative Biolabs offers high quality BsAbs which enable to be applied for receptor signaling interference.

Figure 1. Schematic diagram shows the signal transduction and biological processes mediated by VEGFRs, and a variety of therapeutic strategies to inhibit VEGF signaling. (Kowanetz, M., 2006)

BsAbs Blocking Two Proangiogenics

Angiogenesis is a process in which the new vessels grow from pre-existing ones. It is observed under not only physiological situations but also pathological situations as tumor progression. Compared with physiological angiogenesis which is transiently activated, pathological angiogenesis is usually continuously activated and remains on, causing by a permanent imbalance between pro-angiogenic and anti-angiogenic factors. Among these pro-angiogenic factors. VEGF-A acts an essential part in inducing tumor angiogenesis. VEGF-A, a glycoprotein, is formed by nearly all tumor cells and is observed at elevated levels in the serum of cancer patients. It binds to two key receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1, KDR), and one co-receptor (Neuropilin-1) to exert its pro-angiogenic activities. Creative Biolabs offers high quality BsAbs which enable to simultaneously target VEGFR1 and VEGFR2, promoting your project development.

BsAbs Blocking Two Proinflammatory Cytokines

Cytokines are proteins which help adjust the body’s immune response to infections and trauma. Some can facilitate the healing of wounds, while others, such as proinflammatory cytokines, improve inflammation and enable to induce diseases to progress. Proinflammatory cytokines also contain chemokines which enable to let immune cells called leukocytes get from the blood into infected tissues. Other such cytokines activate molecules are able to bind to the blood vessel walls to let immune cells pass through. Proinflammatory cytokines begin a cascading immune response which starts with an injury, infection, oxygen starvation, or exposure to toxic substances. Creative Biolabs offers high quality BsAbs which enable to simultaneously target two proinflammatory cytokines.

Creative Biolabs has been devoted to BsAb services for years. With our brilliant research team, advanced antibody engineering platform and first class biomedical technology, our scientists are professional and experienced in developing various forms of BsAb for signaling interference.

References

1. Voron, T.; et al. Control of the immune response by pro-angiogenic factors. Frontiers in oncology. 2014, 4.
2. Azeloglu, E. U.; Iyengar, R. Signaling networks: Information flow, computation, and decision making. Cold Spring Harbor perspectives in biology. 2015, 7(4): a005934.
3. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clinical Cancer Research. 2006, 12(17): 5018-5022.